関与物質
| 役割 | 名称 | HCID | 仕込み量 |
|---|
| 反応物 | 1-Fluoronaphthalene | HCID 9450 | — |
| 反応物 | Duloxetine | HCID 60835 | — |
| 反応物 | 2,3:4,6-di-O-Isopropylidene-2-keto-L-gulonic acid | HCID 65420 | — |
| 反応物 | (S)-mandelic acid | HCID 439616 | — |
| 反応物 | 3-(Dimethylamino)-1-(2-thienyl)-1-propanol | HCID 11586409 | — |
| 生成物 | N,N-Dimethyl-3-((naphthalen-1-yl)oxy)-3-(thiophen-2-yl)propan-1-amine | HCID 11573192 | — |
反応手順
The preparation of the enantiomerically pure duloxetine intermediate (S)-AT-OL by its chiral resolution is exemplified in U.S. Pat. No. 5,362,886 (U.S. '886) and in WO 2004/031168, by the use of (S)-(+)-mandelic acid and (−)-2,3:4,6-Di-O-isopropylidene-2-keto-L-gulonic acid, respectively. The U.S. '886 patent describes the preparation of duloxetine by the chiral resolution of N,N-Dimethyl-3-(2-thienyl)-3-hydroxypropanamine (rac-AT-OL) with (S)-mandelic acid (Stage a), its reaction with fluoronaphtalene (Stage b) to give N,N-Dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl)propanamine (DNT), demethylation with phenyl chloroformate (Stage c), basic hydrolysis in the presence of (Stage d), and acidification (Stage e) in accordance with the following Scheme 1.
情報源と証拠
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 特許番号 | US07560573B2 |
|---|
| 出典データセット | uspto-grants-2009_07 |
|---|
| ORD ID | ord-b4e13c2f94f946e48272c9a7635dea3d |
|---|
| 出典メモ | uspto-grants-2009_07 |
|---|